NCT01081574View on ClinicalTrials.gov

Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Allergic RhinoconjunctivitisChronic Urticaria
Interventions
DRUG

Bilastine

10 mg/qd/ 7 days.Oral dispersible tablets

Trial Locations (7)

3052

Royal Children's Hospital, Parkville

6840

Princess Margaret Hospital for Children, Subiaco

13353

Charité - Universitätsmedizin. Campus Virchow-Klinikum. Klinik für Pädiatrie mit Schwerpunkt Pneumologie/Immunologie, Berlin

17176

Karolinska University Hospital. Astrid Lindgren's Hospital, Stockholm

24105

Universitäts-Hautklinik, Kiel

60590

Klinikum der Johann-Wolfgang-Goethe-Universität Frankfurt, Franfurt

751 85

Children's Hospital at Uppsala University Hospital, Uppsala

Sponsors

Lead Sponsor

Faes Farma, S.A.
All Listed Sponsors
lead

Faes Farma, S.A.

INDUSTRY

NCT01081574 - Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU) | Biotech Hunter | Biotech Hunter